Raed M Alnaji1, William Du1, Emmanuel Gabriel1, Smit Singla1, Kristopher Attwood2, Hector Nava1, Usha Malhotra3, Steven N Hochwald1, Moshim Kukar4. 1. Department of Surgical Oncology, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA. 2. Department of Biostatistics, New Center for Excellence, Buffalo, NY, USA. 3. Department of Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA. 4. Department of Surgical Oncology, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA. moshim.kukar@roswellpark.org.
Abstract
INTRODUCTION: Reports of improved survival in patients with pathologic complete response (pCR) to neoadjuvant therapy for esophageal and gastroesophageal junction (GEJ) adenocarcinoma is extrapolated from heterogeneous studies that include squamous cell histology. We sought to determine if pCR is associated with a survival advantage in a homogenous group of patients with esophageal adenocarcinoma. METHODS: This is a single institution analysis of all patients with T2-T4 or node positive esophageal adenocarcinoma treated with neoadjuvant chemoradiotherapy and esophagectomy between 2004 and 2014. Patients were divided into two groups based on pathological response, pCR vs. incomplete pathological response (iPR). Survival outcomes were evaluated using standard Kaplan-Meier methods and multivariable Cox regression models. RESULTS: A total of 205 patients were included in the study: 38 (19 %) patients with pCR and 167 patients (81 %) with iPR. The two groups were similar with respect to clinical stage, age, gender, comorbid conditions, ECOG status, smoking, and alcohol use. Patients in the pCR group had a higher percentage of tumors located in middle third of esophagus (11 vs. 2 %, p = 0.04) while tumor grade was similar in both groups. Median follow-up was 50 months, range 2-109 months. The 3-year overall (OS) and recurrence-free survival (RFS) for iPR was 48 and 39 %, respectively, vs. 86 and 80 % for pCR group, respectively. CONCLUSION: This analysis of a cohort of homogeneous patients with esophageal adenocarcinoma undergoing multimodality therapy showed that pCR is an independent predictor of improved RFS and OS. This data contributes to a growing body of evidence highlighting the benefits of neoadjuvant therapy specific to esophageal adenocarcinoma particularly when pCR is achieved.
INTRODUCTION: Reports of improved survival in patients with pathologic complete response (pCR) to neoadjuvant therapy for esophageal and gastroesophageal junction (GEJ) adenocarcinoma is extrapolated from heterogeneous studies that include squamous cell histology. We sought to determine if pCR is associated with a survival advantage in a homogenous group of patients with esophageal adenocarcinoma. METHODS: This is a single institution analysis of all patients with T2-T4 or node positive esophageal adenocarcinoma treated with neoadjuvant chemoradiotherapy and esophagectomy between 2004 and 2014. Patients were divided into two groups based on pathological response, pCR vs. incomplete pathological response (iPR). Survival outcomes were evaluated using standard Kaplan-Meier methods and multivariable Cox regression models. RESULTS: A total of 205 patients were included in the study: 38 (19 %) patients with pCR and 167 patients (81 %) with iPR. The two groups were similar with respect to clinical stage, age, gender, comorbid conditions, ECOG status, smoking, and alcohol use. Patients in the pCR group had a higher percentage of tumors located in middle third of esophagus (11 vs. 2 %, p = 0.04) while tumor grade was similar in both groups. Median follow-up was 50 months, range 2-109 months. The 3-year overall (OS) and recurrence-free survival (RFS) for iPR was 48 and 39 %, respectively, vs. 86 and 80 % for pCR group, respectively. CONCLUSION: This analysis of a cohort of homogeneous patients with esophageal adenocarcinoma undergoing multimodality therapy showed that pCR is an independent predictor of improved RFS and OS. This data contributes to a growing body of evidence highlighting the benefits of neoadjuvant therapy specific to esophageal adenocarcinoma particularly when pCR is achieved.
Authors: Arta Monir Monjazeb; Greg Riedlinger; Mebea Aklilu; Kim R Geisinger; Girish Mishra; Scott Isom; Paige Clark; Edward A Levine; A William Blackstock Journal: J Clin Oncol Date: 2010-09-27 Impact factor: 44.544
Authors: Ulrich Ronellenfitsch; Matthias Schwarzbach; Ralf Hofheinz; Peter Kienle; Meinhard Kieser; Tracy E Slanger; Bryan Burmeister; David Kelsen; Donna Niedzwiecki; Christoph Schuhmacher; Susan Urba; Cornelis van de Velde; Thomas N Walsh; Marc Ychou; Katrin Jensen Journal: Eur J Cancer Date: 2013-06-22 Impact factor: 9.162
Authors: Pooja R Rohatgi; Stephen G Swisher; Arlene M Correa; Tsung T Wu; Zhongxing Liao; Ritsuko Komaki; Garrett L Walsh; Ara A Vaporciyan; David C Rice; Robert S Bresalier; Jack A Roth; Jaffer A Ajani Journal: Cancer Date: 2006-02-01 Impact factor: 6.860
Authors: Pooja Rohatgi; Stephen G Swisher; Arlene M Correa; Tsung-T Wu; Zhongxing Liao; Ritsuko Komaki; Garrett L Walsh; Ara A Vaporciyan; David C Rice; Jack A Roth; Jaffer A Ajani Journal: Cancer Date: 2005-12-01 Impact factor: 6.860
Authors: Matthias Schmidt; Elfriede Bollschweiler; Markus Dietlein; Stefan P Mönig; Carsten Kobe; Daniel Vallböhmer; Daniel Vallboehmer; Wolfgang Eschner; Arnulf Hölscher; Harald Schicha Journal: Eur J Nucl Med Mol Imaging Date: 2008-12-19 Impact factor: 9.236
Authors: P J Speicher; X Wang; B R Englum; A M Ganapathi; B Yerokun; M G Hartwig; T A D'Amico; M F Berry Journal: Dis Esophagus Date: 2014-09-12 Impact factor: 3.429
Authors: E Bollschweiler; R Metzger; U Drebber; S Baldus; D Vallböhmer; M Kocher; A H Hölscher Journal: Ann Oncol Date: 2008-10-03 Impact factor: 32.976
Authors: Andrew R Davies; James A Gossage; Janine Zylstra; Fredrik Mattsson; Jesper Lagergren; Nick Maisey; Elizabeth C Smyth; David Cunningham; William H Allum; Robert C Mason Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: Emmanuel Gabriel; Kristopher Attwood; William Du; Rebecca Tuttle; Raed M Alnaji; Steven Nurkin; Usha Malhotra; Steven N Hochwald; Moshim Kukar Journal: JAMA Surg Date: 2016-03 Impact factor: 14.766
Authors: Linlin Yang; Changxian Shen; Cory J Pettit; Tianyun Li; Andrew J Hu; Eric D Miller; Junran Zhang; Steven H Lin; Terence M Williams Journal: Clin Cancer Res Date: 2020-03-27 Impact factor: 12.531
Authors: Smita Sihag; Tamar Nobel; Meier Hsu; Sergio De La Torre; Kay See Tan; Yelena Y Janjigian; Geoffrey Y Ku; Laura H Tang; Abraham J Wu; Steven B Maron; Manjit S Bains; David R Jones; Daniela Molena Journal: Ann Surg Date: 2020-11-17 Impact factor: 12.969
Authors: Lucie Hlaváčová; Radek Vrba; Čestmír Neoral; René Aujeský; Martin Stašek; Josef Chudáček; Katherine Vomáčková; David Vrána; Martin Sněhota Journal: Wideochir Inne Tech Maloinwazyjne Date: 2020-11-16 Impact factor: 1.195